Ocugen merged with Histogenics Corporation.

Ocugen, a clinical stage biopharmaceutical company, merged with Histogenics Corporation, a regenerative medicine company. Financial terms were not disclosed. “This transaction with Ocugen reflects the continued commitment of our management team and Board of Directors to deliver value to stockholders and make a difference in patients’ lives. Following a thorough review of strategic alternatives for Histogenics and the NeoCart program, we have determined that a merger with Ocugen will enable Histogenics investors to participate in Ocugen’s broader pipeline of ocular disease and gene therapy opportunities, including several late-stage clinical candidates, and a robust preclinical platform. In addition, we plan to continue to evaluate opportunities to realize additional value from the discontinued NeoCart program over the coming weeks.” Adam Gridley, President of Histogenics.